Confounding Effects of Benign Lung Diseases on Non-Small Cell Lung Cancer Serum Biomarker Discovery

详细信息    查看全文

• 作者：Sridhar Rathinam (1) <br> Aiman Alzetani (1) <br> Jane Starczynski (1) <br> Pala B. Rajesh (1) <br> Stephen Nyangoma (2) <br> Michael J. O. Wakelam (2) <br> Nicholas D. James (2) (3) <br> Wenbin Wei (2) <br> Lucinda J. Billingham (2) <br> Philip J. Johnson (2) <br> Ashley Martin (2) <br> Douglas G. Ward (2) <br>
• 关键词：Lung cancer ; Biomarker ; Serum ; SELDI ; Proteomics
• 刊名：Clinical Proteomics
• 出版年：2009
• 出版时间：December 2009
• 年：2009
• 卷：5
• 期：3-4
• 页码：148-155
• 全文大小：283KB
• 参考文献：1. Parkin DM, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74鈥?08. CrossRef <br> 2. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol. 2000;18:106鈥?5. CrossRef <br> 3. Nesbitt JC, et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 1995;60:466鈥?2. CrossRef <br> 4. Petricoin EF, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst. 2002;94(20):1576鈥?. <br> 5. Poon TCW, et al. Comprehensive proteomic profiling identifies serum proteomic signatures for detection of hepatocellular carcinoma and its subtypes. Clin Chem. 2003;49(5):752鈥?0. CrossRef <br> 6. Ward DG, et al. HCC induced changes in the serum proteome of hepatitis C infected chronic liver disease patients. Br J Cancer. 2006;94(2):287鈥?2. bjc.6602923">CrossRef <br> 7. Ward DG, et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer. 2006;94(12):1898鈥?05. bjc.6603188">CrossRef <br> 8. Yang S-Y, et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer. 2005;5:83. CrossRef <br> 9. Zhang Z, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004;64:5882鈥?0. CrossRef <br> 10. Au J, et al. Deep proteome profiling of sera from never-smoked lung cancer patients. Biomed Pharmacother. 2007;61(9):570鈥?. biopha.2007.08.017">CrossRef <br> 11. Dai S, et al. Discovery and identification of serum amyloid a protein elevated in lung cancer serum. Sci China C Life Sci. 2007;50(3):305鈥?1. CrossRef <br> 12. Han K, et al. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am J Clin Oncol. 2008;31(2):133鈥?. b013e318145b98b">CrossRef <br> 13. Xiao X, et al. A preliminary analysis of non-small cell lung cancer biomarkers in serum. Biomed Environ Sci. 2003;16(2):140鈥?. <br> 14. Han M, et al. Detection and significance of serum protein markers of small-cell lung cancer. J Clin Lab Anal. 2008;22(2):131鈥?. CrossRef <br> 15. Yildiz P, et al. Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol. 2007;2(10):893鈥?01. b013e31814b8be7">CrossRef <br> 16. Taguchi F, et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst. 2007;99(11):838鈥?6. CrossRef <br> 17. Ward D, et al. Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer. 2006;95:1379鈥?3. bjc.6603429">CrossRef <br> 18. Escher N, et al. Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides. Neoplasia. 2007;9(3):254鈥?. CrossRef <br> 19. Koopmann J, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res. 2004;10:860鈥?. CrossRef <br> 20. Munro N, et al. Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer. 2006;116(11):2642鈥?0. CrossRef <br> 21. Scarlett C, et al. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture. Hepatology. 2006;44(3):658鈥?6. CrossRef <br> 22. Koomen JM, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res. 2005;11:1110鈥?. <br> 23. Peng J, et al. Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles鈥攊nitial evaluation using low molecular weight serum peaks. Proteomics. 2009;9(2):492鈥?. CrossRef <br> 24. Ward D. et al. Proteomic profiling of urine for the detection of colon cancer. 2008;6:19. doi:10.1186/1477-5956-6-19 . <br> 25. Ward D, et al. SELDI-TOF-MS determination of hepcidin in clinical samples using stable isotope labelled hepcidin as an internal standard. Proteome Sci. 2008;6:28. CrossRef <br> 26. Kozak K, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics. 2005;5(17):4589鈥?6. CrossRef <br> 27. Miguet L, et al. Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. J Proteome Res. 2006;5(9):2258鈥?9. CrossRef <br> 28. Liu L, et al. Reduced transthyretin expression in sera of lung cancer. Cancer Sci. 2007;98(10):1617鈥?4. CrossRef <br> 29. Allard L, et al. ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke. Proteomics. 2004;4(8):2242鈥?1. CrossRef <br> 30. Fung ET, et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer. 2005;115:783鈥?. CrossRef <br> 31. Song J, et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem. 2006;52(6):1045鈥?3. CrossRef <br> 32. Villanueva J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116(1):271鈥?4. CrossRef <br>
• 作者单位：Sridhar Rathinam (1) <br> Aiman Alzetani (1) <br> Jane Starczynski (1) <br> Pala B. Rajesh (1) <br> Stephen Nyangoma (2) <br> Michael J. O. Wakelam (2) <br> Nicholas D. James (2) (3) <br> Wenbin Wei (2) <br> Lucinda J. Billingham (2) <br> Philip J. Johnson (2) <br> Ashley Martin (2) <br> Douglas G. Ward (2) <br><br>1. Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, B9 5SS, UK <br> 2. School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK <br> 3. University Hospital Birmingham NHS Foundation Trust, Birmingham, B15 2TH, UK <br>
• ISSN：1559-0275

文摘

Introduction Lung cancer is the leading cause of cancer-related death worldwide. The discovery of new biomarkers could aid early diagnosis and monitoring of recurrence following tumor resection. Methods We have prospectively collected serum from 97 lung cancer patients undergoing surgery with curative intent and compared their serum proteomes with those of 100 noncancer controls (59 disease-free and 41 with a range of nonmalignant lung conditions). We initially analyzed serum from 67 lung cancer patients and 73 noncancer control subjects by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry using immobilized metal affinity capture ProteinChip arrays and subsequently validated our findings with an independent analysis of 30 lung cancer patients and 27 noncancer subjects. Results The data from both experiments show many significant differences between the serum proteomes of lung cancer patients and nondiseased control subjects, and a number of these polypeptides have been identified. However, the profiles of patients with benign lung diseases resembled those of lung cancer patients such that very few significant differences were found when these cohorts were compared. Conclusions This report provides clear evidence of the need to account for the confounding effects of benign diseases when designing lung cancer serum biomarker discovery projects.